Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Introduction: Peripheral biomarkers to diagnose Alzheimer's disease (AD) have not been established. Given parallels between neuron and platelet biology, we hypothesized platelet membrane-associated protein changes may differentiate patients clinically defined with probable AD from noncognitive impaired controls. Methods: Purified platelets, confirmed by flow cytometry were obtained from individuals before fractionation by ultracentrifugation. Following a comparison of individual membrane fractions by SDS-PAGE for general proteome uniformity, equal protein weight from the membrane fractions for five representative samples from AD and five samples from controls were pooled. AD and control protein pools were further divided into molecular weight regions by one-dimensional SDS-PAGE, prior to digestion in gel. Tryptic peptides were analyzed by reverse-phase liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Ionized peptide intensities were averaged for each identified protein in the two pools, thereby measuring relative protein abundance between the two membrane protein pools. Log 2-transformed ratio (AD/control) of protein abundances fit a normal distribution, thereby permitting determination of significantly changed protein abundances in the AD pool. Results: We report a comparative analysis of the membrane-enriched platelet proteome between patients with mild to moderate AD and cognitively normal, healthy subjects. A total of 144 proteins were determined significantly altered in the platelet membrane proteome from patients with probable AD. In particular, secretory (alpha) granule proteins were dramatically reduced in AD. Of these, we confirmed significant reduction of thrombospondin-1 (THBS1) in the AD platelet membrane proteome by immunoblotting. There was a high protein-protein connectivity of proteins in other pathways implicated by proteomic changes to the proteins that define secretory granules. Conclusions: Depletion of secretory granule proteins is consistent with a preponderance of post-activated platelets in circulation in AD. Significantly changed pathways implicate additional AD-related defects in platelet glycoprotein synthesis, lipid homeostasis, amyloidogenic proteins, and regulators of protease activity, many of which may be useful plasma membrane-expressed markers for AD. This study highlights the utility of LC-MS/MS to quantify human platelet membrane proteins and suggests that platelets may serve as a source of blood-based biomarkers in neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867 · cited 1×
“Mass spectrometry (MS)-based proteomics has become an essential tool for the detection, identification, and quantification of protein biomarkers from complex mixtures including cells and tissue [26].”
MethodHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 13×
“Abbreviations Aβ: beta amyloid; ACD: acid citrate dextrose; ACN: acetonitrile; AD: Alzheimer’s disease; AGPS: alkylglycerone phosphate synthase; APC: allophycocyanin; Apo: apolipoprotein; APP: amyloid precursor protein; B2M: beta-2 microglobulin; BCA: bicinchoninic acid; CSF: cerebrospinal fluid; CNS: central nervous…”
BackgroundInfluentialThrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis
Christopherson, K. S., Ullian, E. M., Stokes, C. C. A., Mullowney, C. E., Hell, J. W., Agah, A., Lawler, J., Mosher, D. F., Bornstein, P., & Barres, B. A. (2005) · Cell · doi:10.1016/j.cell.2004.12.020 · Cited by 1,688 · cited 1×
“It is secreted from platelets, and also from astrocytes in the CNS, where it may stimulate neuronal synaptogenesis [53].”
BackgroundA68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 1×
“Pathologically, it is characterized by the accumulation of extracellular beta amyloid (Ab) plaques and intracellular tau tangles as well as gliosis and neuronal cell death [1-3].”
BackgroundCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Hirokawa, N., Niwa, S., & Tanaka, Y. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.039 · Cited by 1,138
Oh, J., Takahashi, R., Kondo, S., Mizoguchi, A., Adachi, E., Sasahara, R. M., Nishimura, S., Imamura, Y., Kitayama, H., Alexander, D. B., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00597-9 · Cited by 728
Casserly, I., & Topol, E. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15900-x · Cited by 560
Walther, D. J., Peter, J.-U., Winter, S., Höltje, M., Paulmann, N., Grohmann, M., Vowinckel, J., Alamo-Bethencourt, V., Wilhelm, C. S., Ahnert-Hilger, G., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)01014-6 · Cited by 475 · cited 1×
“For example, both platelets and neurons secrete and respond to neurotransmitters and share many of the same secretory pathways and transporters for neurotransmitter uptake and packaging [12-14].”
BackgroundRyu, J. K., & McLarnon, J. G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00434.x · Cited by 406 · cited 2×
“We speculate that low levels of fibrinogen observed in platelets from patients with AD is complementary to the reported increase in fibrinogen infiltration into AD central nervous system (CNS) tissue associated with Ab depositions and microglial activation [46].”
Background
Cited by
Anticancer Platelet‐Mimicking Nanovehicles
Hu, Q., Sun, W., Qian, C., Wang, C., Bomba, H. N., & Gu, Z. (2015) · Advanced Materials · doi:10.1002/adma.201503323 · Cited by 630
MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease
Kumar, S., Vijayan, M., & Reddy, P. H. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx267 · Cited by 167
Hales, C. M., Dammer, E. B., Deng, Q., Duong, D. M., Gearing, M., Troncoso, J. C., Thambisetty, M., Lah, J. J., Shulman, J. M., Levey, A. I., et al. (2016) · PROTEOMICS · doi:10.1002/pmic.201600057 · Cited by 99
“Ion intensities for identified peptides were extracted in full-MS survey scans of high-resolution and a ratio of the peak intensities for the peptide precursor ion was calculated using in-house software as previously published [10,15,16,21,22].”
MethodSelf-citationNetwork Analysis of a Membrane-Enriched Brain Proteome across Stages of Alzheimer’s Disease
Higginbotham, L., Dammer, E., Duong, D., Modeste, E., Montine, T., Lah, J., Levey, A., & Seyfried, N. (2019) · Proteomes · doi:10.3390/proteomes7030030 · Cited by 32
Self-citation
Metadata
- Authors
- Donovan, L. E., Dammer, E. B., Duong, D. M., Hanfelt, J. J., Levey, A. I., Seyfried, N. T., & Lah, J. J.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2013-06-13
- Volume
- 5
- Issue
- 3
- Pages
- 32-32
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W2118208022
- Cited by
- 43
- References
- 18
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease. https://app.cochat.ai/papers/10.1186/alzrt186
- The paper
- Donovan, L. E., Dammer, E. B., Duong, D. M., Hanfelt, J. J., Levey, A. I., Seyfried, N. T., & Lah, J. J. (2013). Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease. Alzheimer's Research & Therapy. https://doi.org/10.1186/alzrt186
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.